Will Gleevec, Sprycel researchers get a call from Stockholm?

Scientists who worked on the targeted leukemia drugs Gleevec and Sprycel may be in line for the Nobel Prize this year, a prize-prediction expert says. The drugs, sold by Novartis ($NVS) and Bristol-Myers Squibb ($BMY) respectively, represent "a fundamental discovery in medicine...with a fantastic result which is often referred to in terms like 'magic bullet'," analyst David Pendlebury tells Reuters. "It has really given a new paradigm for the treatment of cancer." Report

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.